Literature DB >> 33735274

Hemagglutination Inhibition (HAI) antibody landscapes after vaccination with H7Nx virus like particles.

Hyesun Jang1, Ted M Ross1,2.   

Abstract

BACKGROUND: A systemic evaluation of the antigenic differences of the H7 influenza hemagglutinin (HA) proteins, especially for the viruses isolated after 2016, are limited. The purpose of this study was to investigate the antigenic differences of major H7 strains with an ultimate aim to discover H7 HA proteins that can elicit protective receptor-binding antibodies against co-circulating H7 influenza strains.
METHOD: A panel of eight H7 influenza strains were selected from 3,633 H7 HA amino acid sequences identified over the past two decades (2000-2018). The sequences were expressed on the surface of virus like particles (VLPs) and used to vaccinate C57BL/6 mice. Serum samples were collected and tested for hemagglutination-inhibition (HAI) activity. The vaccinated mice were challenged with lethal dose of H7N9 virus, A/Anhui/1/2013.
RESULTS: VLPs expressing the H7 HA antigens elicited broadly reactive antibodies each of the selected H7 HAs, except the A/Turkey/Italy/589/2000 (Italy/00) H7 HA. A putative glycosylation due to an A169T substitution in antigenic site B was identified as a unique antigenic profile of Italy/00. Introduction of the putative glycosylation site (H7 HA-A169T) significantly altered the antigenic profile of HA of the A/Anhui/1/2013 (H7N9) strain.
CONCLUSION: This study identified key amino acid mutations that result in severe vaccine mismatches for future H7 epidemics. Future universal influenza vaccine candidates will need to focus on viral variants with these key mutations.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33735274      PMCID: PMC7971484          DOI: 10.1371/journal.pone.0246613

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  35 in total

1.  Dissemination, divergence and establishment of H7N9 influenza viruses in China.

Authors:  Tommy Tsan-Yuk Lam; Boping Zhou; Jia Wang; Yujuan Chai; Yongyi Shen; Xinchun Chen; Chi Ma; Wenshan Hong; Yin Chen; Yanjun Zhang; Lian Duan; Peiwen Chen; Junfei Jiang; Yu Zhang; Lifeng Li; Leo Lit Man Poon; Richard J Webby; David K Smith; Gabriel M Leung; Joseph S M Peiris; Edward C Holmes; Yi Guan; Huachen Zhu
Journal:  Nature       Date:  2015-03-11       Impact factor: 49.962

2.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

3.  Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model.

Authors:  Tomy Joseph; Josephine McAuliffe; Bin Lu; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

4.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

5.  Divergent H7 immunogens offer protection from H7N9 virus challenge.

Authors:  Florian Krammer; Randy A Albrecht; Gene S Tan; Irina Margine; Rong Hai; Mirco Schmolke; Jonathan Runstadler; Sarah F Andrews; Patrick C Wilson; Rebecca J Cox; John J Treanor; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

6.  New low-viscosity overlay medium for viral plaque assays.

Authors:  Mikhail Matrosovich; Tatyana Matrosovich; Wolfgang Garten; Hans-Dieter Klenk
Journal:  Virol J       Date:  2006-08-31       Impact factor: 4.099

7.  Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.

Authors:  Falko Schmeisser; Anupama Vasudevan; Swati Verma; Wei Wang; Esmeralda Alvarado; Carol Weiss; Vajini Atukorale; Clement Meseda; Jerry P Weir
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

8.  Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies.

Authors:  Esmeralda Alvarado-Facundo; Russell Vassell; Falko Schmeisser; Jerry P Weir; Carol D Weiss; Wei Wang
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 9.  The CD8 T Cell Response to Respiratory Virus Infections.

Authors:  Megan E Schmidt; Steven M Varga
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

10.  Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.

Authors:  Daniel Stadlbauer; Arvind Rajabhathor; Fatima Amanat; Daniel Kaplan; Abusaleh Masud; John J Treanor; Ruvim Izikson; Manon M Cox; Raffael Nachbagauer; Florian Krammer
Journal:  mSphere       Date:  2017-12-13       Impact factor: 4.389

View more
  2 in total

Review 1.  Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets.

Authors:  Asmaa Hachim; Niloufar Kavian; Sophie A Valkenburg
Journal:  Curr Opin Virol       Date:  2021-08-20       Impact factor: 7.090

2.  Human antibody recognition of H7N9 influenza virus HA following natural infection.

Authors:  Iuliia M Gilchuk; Sandhya Bangaru; Nurgun Kose; Robin G Bombardi; Andrew Trivette; Sheng Li; Hannah L Turner; Robert H Carnahan; Andrew B Ward; James E Crowe
Journal:  JCI Insight       Date:  2021-10-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.